Loading...
A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multi Peptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma.
Rampling, R Peoples, S Mulholland, P James, A Al-Salihi, O Twelves, C McBain, Catherine A Jefferies, S Jackson, A Stewart, W
Rampling, R
Peoples, S
Mulholland, P
James, A
Al-Salihi, O
Twelves, C
McBain, Catherine A
Jefferies, S
Jackson, A
Stewart, W
Citations
Altmetric:
Abstract
To perform a two-cohort, phase 1 safety and immunogenicity study of IMA950 in addition to standard chemo-radiotherapy (CRT) and adjuvant temozolomide in patients with newly diagnosed glioblastoma (GBM). IMA950 is a novel GBM specific therapeutic vaccine containing 11 tumor-associated peptides (TUMAPs), identified on human leukocyte antigen (HLA) surface receptors in primary human GBM tissue.
Description
Date
2016-05-25
Publisher
Collections
Keywords
Type
Article
Citation
A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multi Peptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma. 2016: Clin Cancer Res